147 related articles for article (PubMed ID: 25548522)
21. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors.
Choudhary AK; Abraham G; Patil VM; Menon N; Mandal T; Jacob S; Garg K; Sekar A; Sarma RJ; Reddy L; Nakti D; Mittal N; Bal M; Rane S; Purandare N; Mahajan A; Sable N; Kumar S; Noronha V; Prabhash K
Indian J Surg Oncol; 2022 Mar; 13(1):81-86. PubMed ID: 35462674
[TBL] [Abstract][Full Text] [Related]
22. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
Blair HA; Plosker GL
Target Oncol; 2015 Mar; 10(1):171-8. PubMed ID: 25742918
[TBL] [Abstract][Full Text] [Related]
24. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib and thyroid cancer.
Park C; Perini J; Farmer RW; Fancy T; Monga M; Remick SC
Expert Rev Endocrinol Metab; 2014 Nov; 9(6):561-570. PubMed ID: 30736194
[TBL] [Abstract][Full Text] [Related]
26. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
[No Abstract] [Full Text] [Related]
27. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
28. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
[TBL] [Abstract][Full Text] [Related]
30. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Hoftijzer H; Heemstra KA; Morreau H; Stokkel MP; Corssmit EP; Gelderblom H; Weijers K; Pereira AM; Huijberts M; Kapiteijn E; Romijn JA; Smit JW
Eur J Endocrinol; 2009 Dec; 161(6):923-31. PubMed ID: 19773371
[TBL] [Abstract][Full Text] [Related]
31. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
32. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
[No Abstract] [Full Text] [Related]
33. Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience.
Pitoia F; Abelleira E; Román-González A; Danilovic DLS; Scheffel RS; Maia AL; Hoff AO; Califano I
Thyroid; 2024 Jun; ():. PubMed ID: 38757613
[No Abstract] [Full Text] [Related]
34. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Kuwahara C
Cancer Diagn Progn; 2021; 1(5):491-498. PubMed ID: 35403154
[TBL] [Abstract][Full Text] [Related]
36. Thyroid Gland Malignancies.
Cabanillas ME; Dadu R; Hu MI; Lu C; Gunn GB; Grubbs EG; Lai SY; Williams MD
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1123-43. PubMed ID: 26568552
[TBL] [Abstract][Full Text] [Related]
37. The placebo effect in thyroid cancer: a meta-analysis.
Llavero-Valero M; Guillén-Grima F; Zafon C; Galofré JC
Eur J Endocrinol; 2016 Apr; 174(4):465-72. PubMed ID: 26764417
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer.
Parikh R; Hess LM; Esterberg E; Bhandari NR; Kaye JA
Thyroid Res; 2022 Feb; 15(1):2. PubMed ID: 35151352
[TBL] [Abstract][Full Text] [Related]
39. Radiation-Induced Differentiated Thyroid Cancer Is Associated with Improved Overall Survival but Not Thyroid Cancer-Specific Mortality or Disease-Free Survival.
White MG; Cipriani NA; Abdulrasool L; Kaplan S; Aschebrook-Kilfoy B; Angelos P; Kaplan EL; Grogan RH; Onel K
Thyroid; 2016 Aug; 26(8):1053-60. PubMed ID: 27279587
[TBL] [Abstract][Full Text] [Related]
40. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
Gkountouvas A; Kostoglou-Athanassiou I; Veniou E; Repousis P; Ziras N; Kaldrimidis P
Thyroid; 2010 Jun; 20(6):597-600. PubMed ID: 20553195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
